Industries > Pharma > Top 30 Oncology Drugs Manufacturers 2019

Top 30 Oncology Drugs Manufacturers 2019

AstraZeneca, Merck, Novartis, Amgen, GlaxoSmithKline, Johnson & Johnson, Roche, Pfizer, Eli Lilly, Other Companies

PUBLISHED: 03 May 2019
PAGES: 157
PRODUCT CODE: PHA0417
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0417 Categories: , Tags: , ,

Cancer treating drugs market forms the most lucrative sector in pharmaceuticals. As the ageing population continues to rise across the world, the incidence of cancer will continue to grow, leading to increased spending on cancer-treating medicines. This report lists and discusses the top 30 oncology drugs manufacturers.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 157-page report you will receive 83 tables and 64 figures–all unavailable elsewhere.

The 157-page report provides clear detailed insight into the top 30 oncology drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Assessment of the leading companies in the global oncology drugs market. The list below shows some of the companies that are discussed in the report:
• Abbott Laboratories
• AbbVie
• Amgen
• Astellas Pharma
• AstraZeneca
• Aurora Biophama
• Boehringer Ingelheim
• Bristol-Myers Squibb (BMS)
• Celgene Corporation
• Eli Lilly
• Fresenius Kabi
• Gilead
• GlaxoSmithKline (GSK)
• Grifols
• Johnson & Johnson
• Jounce Therapeutics
• Other companies

Top 30 Oncology Drugs Manufacturers 2019

• For each company, the report provides information and discussion on:
• Company overview
• Product portfolio
• Recent development
• Financial information

• Key questions answered by this report:
• How is the Oncology Drugs Manufacturers market evolving?
• What is driving and restraining the Oncology Drugs Manufacturers market?
• What will be the main driver for the overall market?
• Will leading Oncology Drugs Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?

Visiongain’s study is intended for anyone requiring commercial analyses for the Top 30 Oncology Drugs Manufacturers 2019. You find data, trends and predictions.

Buy our report today Top 30 Oncology Drugs Manufacturers 2019: AstraZeneca, Merck, Novartis, Amgen, GlaxoSmithKline, Johnson & Johnson, Roche, Pfizer, Eli Lilly, Other Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Top 30 Oncology Drugs Manufacturers 2019


Download sample pages

Complete the form below to download your free sample pages for Top 30 Oncology Drugs Manufacturers 2019


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category